Applications

Our new generation of active, dry-powder biologics are temperature-stable and cost-effective to store and transport. For scientists developing high-potential but sensitive biologics, dry-powder formulation means safer, faster commercialization.

Our portfolio of dry powder biologics includes proteins, antibodies, vaccine viruses and more.

ANTIBODIES

ANTIBODY APPLICATIONS

Antibodies have a proven therapeutic modality with over 80 approved for therapeutic use and over 450 in clinical development.

  • CANCER: Bi-specific antibodies have attracted considerable attention recently, with their successful use in cancer immunotherapy. Uniquely, bi-specific antibodies can target two or more tumour antigens to disrupt cancer development. Approx. 50 clinical trials using bispecific antibodies on a range of tumours are currently in progress, with research increasing rapidly.

Ziccum has successfully dried polyclonal antibodies (IgG) in active, dry- powder form. Formulation as dry powder rather than solution significantly improves stability. Current conventional drying techniques like freeze drying can be harsh and damaging to sensitive antibodies. Ziccum’s LaminarPace spray drying method gently air-dries them at room temperature, with little force and high yields.

Our polyclonal antibody IgG remained active after drying, with virtually no difference in activity, despite polyclonal antibodies containing many different types of clones. Particles in the dry formulation were in uniform shape with a narrow particle size distribution range.

ADENOVIRUS

ADENOVIRUS APPLICATIONS

Adenovirus vectors are an increasingly popular platform in the development of a wide range of new vaccines as well as gene therapies.

  • VACCINES: Adenoviruses are a widely used platform in vaccine design. With their strong immunogenicity and safety profiles, adenoviruses are a key component in a wide range of new vaccines.
  • GENE THERAPY: In 2018, 2600 gene therapy clinical trials were completed, approved or ongoing. Adenovirus is being used as the vector platform for gene therapy treatments for Parkinson’s, cystic fibrosis, muscular dystrophy and Huntingdon’s.

Adenovirus is a key ingredient in vaccines against Malaria, Ebola, meningitis and HIV—diseases which affect over 100 million people globally every year. Ziccum’s active, temperature-stable, dry-powder formulation of Adenovirus can be stored at +40°C for at least one week with no loss of active ingredient.

This enables vaccine developers to gain WHO CTC-approval. CTC (Controlled Temperature Chain) labelling is a new part of the WHO’s mission to vaccinate more people worldwide without having to rely on costly, complex cold-chain refrigeration systems. CTC approval requires that vaccines can be stored at +40 °C for at least three days.

Dry powder adenovirus could potentially lead to a significant global increase in the number of people worldwide who can be vaccinated.

Developing new patents in dry-powder biologics

We aim to seek patents on all of the new dry-powder versions of biologic therapies we’re developing—giving a powerful competitive edge to biologic pharma developers. In a market forecast to be worth 25 BUSD by 2021, access to our patents via licenses will deliver a formidable competitive advantage.

Harnessing the Intellectual Property rights on new dry powder versions of therapies is a key component of Ziccum’s business plan. Ziccum intends to use its LaminarPace technology to create new, dry-powder versions of biologic therapies. Each substance will be available for licensing for pharmaceutical companies looking to build and protect their product portfolio.

LaminarPace: Cracking the Cold Chain

LaminarPace is a patented technology that gently dries chemicals, vaccines, biologics and drug substances at room temperature, keeping their active ingredient intact. It has successfully dried over 100 different types of biologics and chemicals, including peptides and antibodies.

Current conventional drying technologies either freeze or bake substances. Operating at -80 °C or +80 °C, it means there is little chance of delicate, temperature-sensitive biologics remaining active after being dried.

By micronizing substances at room temperature, LaminarPace produces robust, active dry powder versions of delicate biologics, peptides, proteins and antibodies. 80% of biologic therapies are currently formulated as liquid solutions, making them costly and difficult to handle and transport.

How does LaminarPace work?

LaminarPace is a patented technology that gently dries chemicals, vaccines, biologics and drug substances at room temperature, keeping their active ingredient intact. It has successfully dried over 100 different types of biologics and chemicals, including peptides and antibodies.

 

Who is behind LaminarPace?

LaminarPace was invented by world aerosol authority Dr Per Gerde, Associate Professor of Inhalation Toxicology, Institute of Environmental Medicine, Karolinska Institutet.

As CSO of Inhalation Sciences AB (ISAB), Dr Gerde originally developed LaminarPace for drying pharmaceutical Candidate Drugs to be used in ISAB’s core technology, PreciseInhale.

Realizing that LaminarPace had an extensive number of uses beyond ISAB’s core market, in 2017 LaminarPace was spun-out from ISAB into Ziccum AB—its goal to commercialize the technology towards a wider audience.